Sanofi opines on Danish government's Bavarian contract: Single supplier would be a mistake

Sanofi praises Danish government despite canceling the national vaccine production tender. Even so, the company thinks it would be problematic if the state were to bet solely on Bavarian Nordic for domestic vaccine preparedness.

Manager at Sanofi Per H. Aabakken participated in the market hearing held by the Danish SSI to investigate conditions for a potential vaccine production tender, before it was cancelled. | Photo: Sanofi/PR

The Danish government should exercise caution in betting solely on a single contract with Bavarian Nordic as the solution to its ambitions of a national vaccine preparedness.

At least this is the opinion of pharmaceutical company Sanofi, which was on of the six companies courting the government for a role in the future national vaccine production. 

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs